Association between Nonalcoholic Fatty Liver Disease (NAFLD) and Osteoporotic Fracture in Middle-Aged and Elderly Chinese

Li, Mian; Xu, Yu; Xu, Min; Ma, Lingying; Wang, Tiange; Liu, Yu; Dai, Meng; Chen, Yuhong; Lu, Jieli; Liu, Jianmin; Bi, Yufang; Ning, Guang

doi:10.1210/jc.2011-3010

Cited by 122 publications

(137 citation statements)

References 32 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Moon and colleagues observed reduced BMD of the lumbar spine in postmenopausal patients with NAFLD, regardless of the presence of MS, and after taking into account other risk factors for low BMD (body mass index, age, and smoking) [Moon et al 2012]. Decreased BMD in NAFLD appears to be independent of sex, which is consistent with the results of a retrospective study involving more than 7000 men, in which the presence of NAFLD was associated with a 2.5-fold increased risk of osteoporotic fractures [Li et al 2012]. Purnak and colleagues did not observe a relationship between simple steatosis and BMD [Purnak et al 2012].…”

Section: Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepasupporting

confidence: 84%

Osteoporosis in liver disease: pathogenesis and management

Handzlik-Orlik

Holecki

Wilczyński

et al. 2016

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Osteoporosis affects a substantial proportion of patients with chronic liver disease. Pathologic fracture in osteoporosis significantly affects quality of life and life expectancy. By some estimates, 40% of patients with chronic liver disease may experience osteoporotic fracture. In this study we review the pathogenesis, diagnosis and treatment of specific liver disease entities and their relation to osteoporosis.

show abstract

Section: Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepasupporting

confidence: 84%

Osteoporosis in liver disease: pathogenesis and management

Handzlik-Orlik

Holecki

Wilczyński

et al. 2016

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

show abstract

“…Patients with NAFLD have been reported to have decreased BMD [34,35] and increased risk of fractures [36], although not all studies concur [37,38]. In our population we found no difference in BMD or bone turnover markers between NAFLD patients and controls; however, sclerostin levels were positively correlated with BMD in our patients, in accordance with previous studies in different populations; we previously reported, for the first time, a positive correlation between sclerostin and BMD in postmenopausal osteoporosis [39], a finding validated by other authors in distinct metabolic bone diseases [40,41].…”

Section: Discussionmentioning

confidence: 99%

Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease

et al. 2015

View full text Add to dashboard Cite

There is increasing evidence for bone-liver interplay. The main aim of this study was to determine serum sclerostin and Dickkopf (DKK)-1 levels in patients with nonalcoholic fatty liver disease (NAFLD) and their association with the disease severity. Patients with biopsy-proven NAFLD, 13 with nonalcoholic simple steatosis (SS) and 14 with steatohepatitis (NASH), and 20 gender-, age-, body mass index- and waist circumference-matched controls were enrolled. Serum sclerostin, DKK-1, bone turnover markers, vitamin D, insulin and standard biochemical and hematologic parameters were measured; lumbar spinal dual-energy X-ray absorptiometry was performed. We observed that there was a progressive decline in serum sclerostin levels from the controls (76.1 ± 6.8) to SS (53.5 ± 6.4) and NASH (46.0 ± 8.1 pmol/l) patients (p = 0.009); in adjusted pairwise comparisons, sclerostin was significantly higher in the controls than in NASH patients (p = 0.012). Although serum DKK-1 did not differ between groups (p = 0.135), there was a trend toward U-shaped distribution (controls 35.8 ± 2.8; SS 27.3 ± 2.9; NASH 36.8 ± 4.4 pmol/l). Higher DKK-1 levels were independently associated with NASH. Regarding specific histological lesions, DKK-1 levels were marginally lower in NAFLD patients with lower (≤33 %) than higher (>33 %) steatosis grade (27.7 ± 3.1 and 38.8 ± 4.7 pmol/l, respectively; p = 0.049). No other significant difference was observed within histological lesions. In conclusion, serum sclerostin levels were lower in NASH patients than in controls. DKK-1 levels were independently associated with NASH in NAFLD patients. The potential importance of these findings indicates a possible bone-liver interaction and warrants further investigation.

show abstract

“…Several recent cross-sectional and case-control studies involving both adults and children or adolescents have consistently demonstrated that the prevalence of decreased BMD (as measured by dual-energy X-ray absorptiometry) is significantly increased in patients with NAFLD (Table 1) [9][10][11][12][13][14][15][16][17].…”

Section: Epidemiological Evidence Linking Nafld With Low Bmdmentioning

confidence: 99%

Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?

Targher

Lonardo

Rossini

2015

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

Association between Nonalcoholic Fatty Liver Disease (NAFLD) and Osteoporotic Fracture in Middle-Aged and Elderly Chinese

Abstract: The presence of NAFLD was significantly associated with a recent history of osteoporotic fracture in middle-aged and elderly Chinese men.

Cited by 122 publications

References 32 publications

Osteoporosis in liver disease: pathogenesis and management

Osteoporosis in liver disease: pathogenesis and management

Circulating sclerostin and Dickkopf-1 levels in patients with nonalcoholic fatty liver disease

Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?

Contact Info

Product

Resources

About